The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope
- 17 November 2008
- journal article
- research article
- Published by Elsevier in Molecular Immunology
- Vol. 46 (4) , 705-712
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Nanotechnology in vaccine deliveryAdvanced Drug Delivery Reviews, 2008
- CPG 7909 Adjuvant plus Hepatitis B Virus Vaccination in HIV‐Infected Adults Achieves Long‐Term Seroprotection for Up to 5 YearsClinical Infectious Diseases, 2008
- The immunogenic CBD1 peptide corresponding to the caveolin-1 binding domain in HIV-1 envelope gp41 has the capacity to penetrate the cell membrane and bind caveolin-1Molecular Immunology, 2008
- Development of TLR9 agonists for cancer therapyJournal of Clinical Investigation, 2007
- HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41Journal of Pharmacy and Pharmacology, 2006
- CELL BIOLOGY OF ANTIGEN PROCESSING IN VITRO AND IN VIVOAnnual Review of Immunology, 2005
- An ingenious design for peptide vaccinesVaccine, 2005
- The Caveolin-1 Binding Domain of HIV-1 Glycoprotein gp41 Is an Efficient B Cell Epitope Vaccine Candidate against Virus InfectionImmunity, 2004
- ELISA analysis of β‐secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathwaysJournal of Neurochemistry, 2002
- Peptide‐induced memory (IgG) response, cross‐reactive with native proteins, requires covalent linkage of a specific B cell epitope with a T cell epitopeEuropean Journal of Immunology, 1993